ABSTRACT
In 2023, no new active pharmaceutical ingredients were released on the German market for horses and food-producing animals. Two established veterinary active pharmaceutical ingredients became available for additional species: The phosphorus compound butafosfan was also approved for horses, dogs, and cats and the mineral sodium chloride as an isotonic sodium chloride solution was also approved for rabbits and guinea pigs. In addition, for small animals, there were new releases of an agent (pergolidmesilate) in a novel pharmaceutical formulation and a lower content of the active ingredient, one drug (fluralaner) in a smaller package size as well as one drug (oxalic acid dehydrate) with a new route of administration. Furthermore, one combination of active ingredients (diprophylline+heptaminol) is available on the market for horses and food producing animals again.
Subject(s)
Veterinary Drugs , Animals , Horses , Germany , Dogs , Cats , Guinea Pigs , RabbitsABSTRACT
In 2023, 2 novel pharmaceutical agents for small animals were released on the German market: the structural but non-functional analog of the inhibitory neurotransmitter gamma-aminobutyric acid pregabalin with an anxiolytic active component and the dopamine agonist ropinirole in form of eye drops to induce vomiting. Two established active veterinary pharmaceutical ingredients became available for additional species: The phosphorus compound butafosfan was additionally approved for horses, dogs and cats and the mineral sodium chloride as an isotonic sodium chloride solution was also approved for rabbits and guinea pigs. In addition, for small animals, there were new releases of an agent (dexamethasone) in a novel pharmaceutical formulation, one drug with a new route of administration (hydrocortisone aceponate), one drug with a new content of the active ingredient (firocoxib) as well as one veterinary drug with a new combination of active ingredients in a novel pharmaceutical formulation (gentamicin+mometasone+posaconazole). Furthermore, one combination of active ingredients (diprophylline+heptaminol) is available on the market for small animals again.
Subject(s)
Veterinary Drugs , Animals , Dogs , Cats , Horses , Germany , RabbitsABSTRACT
In 2022, 3 novel pharmaceutical A: gents for small animals were released on the German market: the peripheral selective α2-adrenoceptor antagonist vatinoxan in combination with medetomidine (Zenalpha®), mesenchymal stem cells from the umbilical cord of horses (DogStem®) and the ectoparasitic agent tigolaner in combination with emodepside and praziquantel (Felpreva®). No active substance received an animal species extension. In addition, for small animals, there were new releases of four active ingredients in a novel pharmaceutical formulation (acetylcysteine, clindamycin, metoclopramide, oclacitinib maleate), one drug with a new content of the active ingredient (firocoxib) and one veterinary drug with a new combination of active ingredients in a novel pharmaceutical formulation (ketoconazole+marbofloxacin+prednisolone).
Subject(s)
Veterinary Drugs , Animals , HorsesABSTRACT
In 2022, one novel pharmaceutical agent was released on the German market for horses or food-producing animals: An injection suspension for horses containing tenogenic primed equine allogeneic peripheral blood-derived mesenchymal stem cells as the active ingredient (RenuTend®) is now available. The authorization of one established veterinary active ingredient was extended to an additional species: The synthetic prostaglandin F2α-analogue cloprostenol (Syncroprost®) received approval for goats. Additionally, for 2 active ingredients (paracetamol, suxibuzone), drugs with a higher content of the active ingredient were launched on the market for horses and food-producing animals.
Subject(s)
Veterinary Drugs , Animals , Horses , Goats , AcetaminophenABSTRACT
The new pharmaceutical regulations for veterinary medicinal products introduced in the course of the EU harmonization also have an impact on pharmacotherapy of honey bee colonies in Germany. In particular, the requirement to use veterinary medicinal products in accordance with the terms of the marketing authorization not only restricts the veterinarians' freedom of therapy, but also marks the end of off-label use of approved varroacides in honey bees not subject to pharmacy requirements by beekeepers. A deviation from the terms of the marketing authorization is only possible in the case of a so-called therapeutic emergency in the reclassification, irrespective of the sales demarcation/limitation. If such a situation exists, however, veterinary medicinal products for honey bees from other member states of the European Union may already be used in the first reclassification level, even if veterinary medicinal products with the same active ingredient are available in Germany. For this reason, the article discusses not only the impact of the required adherence to the marketing authorization, but also additional treatment options for honey bees in consequence to the harmonisation of the internal market.
Subject(s)
Veterinary Drugs , Animals , Bees , GermanyABSTRACT
In 2021, one novel pharmaceutical agent for horses or food-producing animals was released on the German market, making the anti-haemorrhagic etamsylate (Hemosilate) available for horses, cattle, pigs, sheep, goats, dogs and cats, for the first time. The authorization of one established veterinary active ingredient was extended to an additional species: The endectocide eprinomectin (Eprecis®) from the group of macrocyclic lactones was also approved for sheeps and goats. Additionally, two veterinary formulations with a new active substance content (bromhexine, tiamulin) and one active ingredient in a novel pharmaceutical formulation (indigo carmine stained intramammary suspension with heavy bismuth subnitrate) appeared on the market. Furthermore, one active ingredient (oxytetracycline) is again available for horses on the market for horses and food-producing animals.
Subject(s)
Cat Diseases , Cattle Diseases , Dog Diseases , Goat Diseases , Horse Diseases , Sheep Diseases , Swine Diseases , Animals , Cats , Cattle , Dogs , Goats , Horse Diseases/drug therapy , Horses , Sheep , SwineABSTRACT
In 2021, 8 novel pharmaceutical agents for small animals were released on the German market: The specific monoclonal antibodies bedinvetmab (Librela®) and frunevetmab (Solensia®), the cyclooxygenase-2 inhibitor enflioxib (Daxocox®), the ectoparasitic esafoxolaner (NexGard® Combo) of the isoxazoline group, the anti-haemorrhagic etamsylate (Hemosilate), the antidepressant mirtazapine (Mirataz®), the alpha-selective sympathomimetic tetryzoline for ophthalmic use (Zolicep®) and the cytostatic tigilanol tiglate (Stelfonta®). No active substance received an animal species extension. In addition, for small animals, there were new releases of two agents in a novel pharmaceutical formulation (cefalexin, gentamicin), five drugs with a new content of the active ingredient (metronidazole, pimobendan, thiamazole, tramadol, trilostane), one veterinary drug with a new combination of active ingredients (lotilanerâ +â milbemycin oxime), one drug with a new route of administration (propofol) and furthermore two temporarily non-available active ingredients for certain animal species were reapproved in new drugs (levothyroxine for cats and oxytetracycline for dogs and cats).
Subject(s)
Cat Diseases , Dog Diseases , Tramadol , Veterinary Drugs , Animals , Anti-Inflammatory Agents, Non-Steroidal , Cats , DogsABSTRACT
In 2020, one novel pharmaceutical agent for small animals, the ACTH analog tetracosactide for the assessment of adrenocortical function in dogs, were released on the German market. Two established veterinary active pharmaceutical ingredients became available for additional species: The dissociative anesthetic ketamine is now also authorized for hamsters, mice, and rats; and the osmotic laxative lactulose is approved for use also in dogs and cats. Additionally, 3 veterinary drugs with a new combination of active ingredients (mometasone + terbinafine + florfenicol, sarolaner + moxidectin + pyrantel), an agent (tetracaine) in a novel pharmaceutical formulation, one drug (lidocaine) with a new route of administration as well as a crystalloid balanced whole electrolyte solution with a potential base excess (BEpot) of 0 mmol/l were launched on the market for small animals.
Subject(s)
Cat Diseases , Dog Diseases , Rodent Diseases , Veterinary Drugs , Animals , Cats , Dogs , Mice , RatsABSTRACT
In 2020, one novel pharmaceutical agent for horses or food-producing animals was released on the German market, rendering the inhaled glucocorticoid ciclesonide (Aservo EquiHaler®) available for horses for the first time. The authorization of one established veterinary active ingredient was extended to an additional species: The anthelmintic fenbendazole (Gallifen®) from the benzimidazole group is now also authorized for pheasants. Additionally, 3â veterinary drugs with a new combination of active ingredients (ketoprofenâ +â tilmicosin, ketoprofenâ +â tulathromycin, prednisoloneâ +â lidocaine), 3â agents in a novel pharmaceutical formulation (florfenicol, sodium hydrogen carbonate, prednisolone), one drug (fluralaner) in a new package size as well as a crystalloid balanced whole electrolyte solution with a potential base excess (BEpot) of 0â mmol/l were launched on the market for horses and food-producing animals.
Subject(s)
Anti-Infective Agents , Veterinary Drugs , Animals , Horses , MeatABSTRACT
Infestation with Tropilaelaps mites is a disease that damages the bee brood and is subject to compulsory notification for Apis mellifera. Despite the high risk of introduction of this disease, it is not yet present in Europe. In order to prevent introduction and spreading, mites of Tropilaelaps size must be identified immediately when found in debris or in covered bee brood. In the present case, Parasitellus fucorum was identified as an additional mite species in the debris of Apis mellifera possessing a potential for misperception as Tropilaelaps spp.
Subject(s)
Acari/classification , Bees/parasitology , Acari/anatomy & histology , Animals , Diagnosis, Differential , EuropeABSTRACT
In 2019, one novel pharmaceutical agent for horses or food-producing animals was released on the German market: An injection suspension for horses containing chondrogenic-induced equine allogeneic peripheral blood-derived mesenchymal stem cells as the active ingredient (ArtiCell® Forte) is now available. Two established veterinary active pharmaceutical ingredients became accessible for additional species: a salicylanilide anthelmintic oxyclozanide (Distocur®) for the treatment and control of fascioliasis in sheep as well as a type-I synthetic pyrethroid permethrin (Z-Itch®), which now has additionally been authorized for donkeys. Additionally, one veterinary drug with a new combination of active ingredients (toltrazuril + gleptoferron), 2 drugs (permethrin, omeprazole) in a new pharmaceutical formulation, one drug (lidocaine) with a novel route of administration, one drug (amprolium) with a higher content of the active ingredient, as well as one active substance (butylscopolaminium bromide) in mono-preparation have been launched on the market for horses and food-producing animals.
Subject(s)
Veterinary Drugs/administration & dosage , Animals , Cattle , Drug Combinations , Horses , Mesenchymal Stem Cells/chemistry , Sheep , Swine , Veterinary Drugs/pharmacology , Veterinary Drugs/therapeutic useABSTRACT
In 2019, 2 novel pharmaceutical agents for small animals were released on the German market: The non-steroidal, non-cyclooxygenase inhibiting anti-inflammatory agent grapiprant (Galliprant®) of the piprant class as well as fluorescein (Ophtorescein®), a xanthen dye-based diagnostic agent for corneal defects. One substance was authorized for an additional species: The antidiabetic protamine zinc insulin of human origin (ProZinc®) is now additionally authorized for dogs. Additionally, one veterinary drug with a new combination of active ingredients (fluralanerâ +â moxidectin), 5 agents in a novel pharmaceutical formulation (acepromazine, chloramphenicol, dexamethasone, metronidazole, torasemide), one drug (lidocaine) with a new route of administration, as well as one agent (apomorphine) in a new primary packaging with extended opening stability have been launched on the market for small animals.
Subject(s)
Drug Therapy/veterinary , Veterinary Drugs , Animals , Dogs , Drug Combinations , Germany , Sulfonylurea CompoundsABSTRACT
In 2018, two active pharmaceutical ingredients were released on the German market for small animals: the ectoparasiticide of the isoxazoline group Lotilaner (Credelio®) and the opioid analgesic Tramadol (Tralieve®). Two established veterinary active pharmaceutical ingredients became available for additional species: the nonsteroidal anti-inflammatory drug Meloxicam (Metacam®) from the oxicam group for guinea pigs and the inhalant anesthetic Sevoflurane (Sevoflo®) from the group of halogenated hydrocarbon compounds, which has additionally been authorized for cats. With the combination of Benzylpenicillin-Benzathine and Benzylpenicillin-Procaine, one temporarily non-available combination of active ingredients was reapproved in new drugs. Additionally, one drug with a new pharmaceutical form and one drug with a higher content of the active ingredient have been launched on the market for small animals.
Subject(s)
Anti-Bacterial Agents/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antihypertensive Agents/administration & dosage , Antiparasitic Agents/therapeutic use , Platelet Aggregation Inhibitors/administration & dosage , Animals , Cats , Dexamethasone/administration & dosage , Dogs , Ectoparasitic Infestations/drug therapy , Ectoparasitic Infestations/veterinary , Guinea Pigs , Injections/veterinary , Isoxazoles/administration & dosage , Isoxazoles/therapeutic use , Meloxicam/therapeutic use , Penicillin G Benzathine/administration & dosage , Penicillin G Procaine/administration & dosage , Sevoflurane/administration & dosage , Solutions , Suspensions , Tablets , Telmisartan/administration & dosage , Tramadol/administration & dosage , Tramadol/therapeutic useABSTRACT
In 2018, no new active pharmaceutical ingredients were released on the German market for horses or food-producing animals. One established veterinary active pharmaceutical ingredient became available for an additional species: the inhalant anesthetic Isoflurane (Isofluran Baxter® vet) from the group of halogenated hydrocarbon compounds was additionally authorized for pigs (piglets). With Acepromazine, Mepivacaine and Oxyclozanide, three temporarily non-available active ingredients were reapproved in new drugs. Additionally, one drug with a new combination of active ingredients and one drug with a new pharmaceutical form were launched on the market for horses and food-producing animals.
Subject(s)
Animals, Domestic , Drug Therapy/veterinary , Horses , Veterinary Drugs , Acepromazine , Anesthetics, Inhalation , Anesthetics, Local , Animals , Anti-Bacterial Agents , Anti-Inflammatory Agents, Non-Steroidal , Antiplatyhelmintic Agents , Bees , Dopamine Antagonists , Drug Therapy/trends , Germany , Isoflurane , Meloxicam , Mepivacaine , Oxalic Acid , Oxyclozanide , Swine , Thiamphenicol/analogs & derivativesABSTRACT
In 2017, no new active pharmaceutical ingredients were released on the German market for horses or food-producing animals. Four established veterinary active pharmaceutical ingredients became available for additional species: the ectoparasitic Fluralaner (Exzolt®) of the isoxazoline group was additionally authorized for chickens, the macrolide antibiotics Gamithromycin (Zactran®) and Tulathromycin (Draxxin®) for sheep and the nonsteroidal anti-inflammatory drug Tolfenamic Acid (Tolfedol®) from the fenamate group for cattle and pigs. Additionally, one drug with a new combination of active ingredients, one drug with a new pharmaceutical form and one drug with a new mode of administration have been launched on the market for horses and food-producing animals.
Subject(s)
Animals, Domestic , Anti-Infective Agents , Horse Diseases/drug therapy , Veterinary Drugs , Animals , Anti-Inflammatory Agents , Cattle , Chickens , Horses , SwineABSTRACT
In 2017 the active pharmaceutical ingredient Lokivetmab (Cytopoint®), a caninized anti-canine Interleukin 31 monoclonal antibody, was released on the German market for small animals. One substance was authorized for an additional species. Sarolaner, an ectoparasiticide of the isoxazoline group, is now authorized for use in combination with Selamectin (Stronghold® Plus) additionally for cats. The testosterone derivate Nandrolone (Nandrosol®) and the combination of the benzodiazepine Zolazepam with the "dissociative anesthetic" Tiletamine (Zoletil®) were once again authorized. Furthermore, two veterinary drugs with a new combination of active ingredients, one drug with a new active ingredient and two veterinary drugs with a new pharmaceutical form have been launched on the market for small animals.
Subject(s)
Veterinary Drugs , Animals , Cats , DogsABSTRACT
In 2016, only one newly developed active pharmaceutical ingredient for horses and food-producing animals was released on the German market for veterinary drug products. The immunomodulator Pegbovigrastim is now available as an injection solution for cattle (Imrestor®). Four established veterinary active pharmaceutical ingredients are available for further species: the ectoparasitic Amitraz (Apitraz®) from the triazapentadiene group was additionally authorized for honeybees, the expectorant Bromhexine (Exflow® Vet) for chickens, turkeys and ducks and the macrolide antibiotic Gamithromycin (Zactran®) for pigs. The dopamine D2 receptor agonist Cabergolin (Velactis®) was released for dairy cattle. However, the authorization was suspended a few months after market introduction because of severe side effects. Additionally, one veterinary drug with a new combination of active ingredients as well as one active substance in mono-preparation have been launched on the market for horses and food producing animals.
Subject(s)
Horse Diseases/drug therapy , Horses , Livestock , Veterinary Drugs , Animals , Animals, Domestic , Cattle , Chickens , SwineABSTRACT
In 2016, two active pharmaceutical ingredients were released on the German market for small animals: the mineralocorticoid Desoxycorticosterone (Zycortal®) and Sarolaner (Simparica®), an ectoparasiticide of the isoxazoline group. One substance has been authorized for an additional species; Fluralaner (Bravecto®), also an ectoparasiticide of the isoxazoline group, is now authorized for use in cats. Additionally, one veterinary drug with a new combination of active ingredients, one active substance in mono-preparation and two veterinary drugs with a new pharmaceutical form have been launched on the market for small animals.
ABSTRACT
In 2015, four newly developed active pharmaceutical ingredients for horses and food-producing animals were released on the German market for veterinary drug products. These were the bisphosphonate Clodronic Acid (Osphos®), the 5-hydroxytryptamine (2A) receptor antagonist Ketanserin (Vulketan®), the aminoglycoside antibiotic Paromomycin (Parofor®) and the antibiotic Thiamphenicol (TAF Spray®) from the fenicole group. With Chlorphenamine, a temporary not available active ingredient was reapproved in a new drug. Furthermore, three veterinary drugs with a new formulation as well as one product with a new strength and two products with a new combination of active pharmaceutical ingredients have been launched.
